Lv31
290 积分 2023-07-04 加入
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
6小时前
待确认
Efficacy and safety of telitacicept for myasthenia gravis in real-world practice and exploratory outcomes in the elderly subgroup
6天前
已完结
Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis
6天前
已完结
A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma After Lenalidomide Exposure
12天前
已关闭
Treating Multiple Myeloma Patients With Oral Therapies
13天前
已完结
POSTER: MM-691 Phase 3 AQUILA Study of Daratumumab Monotherapy Versus Active Monitoring in Patients With High-Risk Smoldering Multiple Myeloma (SMM)
23天前
已关闭
Renal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005–2019
24天前
已完结
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
1个月前
已完结
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
1个月前
已完结
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial
1个月前
已完结
皖公网安备34019202002308
